4 terminated, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Dordaviprone (ONC201): new trials by email Literature Review of Dordaviprone (ONC201) trials Research Report on Dordaviprone (ONC201)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo - H3 K27M, Glioma | Phase 3 | Recruiting | Jazz Pharmaceuticals | 510 | 2023-01-23 | 2026-04-16 |
| ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Dordaviprone (ONC201) - Endometrial Cancer Recurrent | Phase 2 | Terminated | Jazz Pharmaceuticals | 27 | 2018-03-21 | 2024-12-24 |
| ONC201 in Pediatric H3 K27M Gliomas Dordaviprone (ONC201) - Diffuse Intrinsic Pontine Glioma, Glioma, Malignant | Phase 1 | Terminated | Jazz Pharmaceuticals | 134 | 2018-01-25 | 2025-02-14 |
| ONC201 in Adults With Recurrent H3 K27M-mutant Glioma Dordaviprone (ONC201) - Glioma | Phase 2 | Terminated | Jazz Pharmaceuticals | 73 | 2017-10-30 | 2025-07-28 |
| Oral ONC201 in Adult Recurrent Glioblastoma Dordaviprone (ONC201) - Glioblastoma, Diffuse Midline Glioma | Phase 2 | Terminated | Jazz Pharmaceuticals | 84 | 2016-01-01 | 2024-12-24 |
Glioma (3) · Diffuse Intrinsic Pontine Glioma (1) · Glioblastoma (1)
United States (5) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · Denmark (1) · Germany (1) · Hong Kong (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Singapore (1) · South Korea (1)